NCT01487733 is a clinical trial of gene expression analysis in Head and Neck Cancer, sponsored by Eastern Cooperative Oncology Group.

Who is sponsoring NCT01487733?

NCT01487733 is sponsored by Eastern Cooperative Oncology Group.

What drugs are being tested in NCT01487733?

Interventions in NCT01487733: gene expression analysis, in situ hybridization, immunohistochemistry staining method, laboratory biomarker analysis.

What condition does NCT01487733 study?

NCT01487733 studies Head and Neck Cancer.

Is NCT01487733 still recruiting?

NCT01487733 is currently completed. Last updated 17 May 2017.

Last reviewed 2017-05-17 · How we verify

NCT01487733

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarkers in Tissue Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on ECOG-E1395 and ECOG-E3301

Completed Last updated 17 May 2017

What this trial tests

trial testing gene expression analysis in Head and Neck Cancer in 155 participants. Completed in 22 January 2012.

Timeline

22 December 2011

Primary endpoint
22 January 2012

22 January 2012

Quick facts

Lead sponsor	Eastern Cooperative Oncology Group
Status	Completed
Study type	OBSERVATIONAL
Enrollment	155
Start date	22 December 2011
Primary completion	22 January 2012
Estimated completion	22 January 2012

Drugs / interventions tested

gene expression analysis
in situ hybridization
immunohistochemistry staining method
laboratory biomarker analysis — full drug profile →

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →

Sponsor

Eastern Cooperative Oncology Group

Who can join

Adults 18 to 120, any sex, with Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. PURPOSE: This research study is studying biomarkers in tissue samples from patients with recurrent or metastatic head and neck cancer treated on ECOG-E1395 and ECOG-E3301.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.
Argiris A, Li S, Ghebremichael M, Egloff AM, et al · · 2014 · cited 74× · PMID 24799460 · DOI 10.1093/annonc/mdu167
Epithelial‑derived head and neck squamous tumourigenesis (Review).
Shirima CA, Bleotu C, Spandidos DA, El-Naggar AK, et al · · 2024 · cited 2× · PMID 39219259 · DOI 10.3892/or.2024.8800

Verify or expand the search:

Other trials of gene expression analysis

Trials testing the same drug.

NCT01567722 — Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies · terminated
NCT01381705 — Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma · completed
NCT01209299 — Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated Wi · completed
NCT01505712 — Biomarkers in Tissue Samples From Patients With Hodgkin Lymphoma Enrolled on ECOG-2496 Clinical Trial · completed
NCT01406782 — DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E440 · completed

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Other Eastern Cooperative Oncology Group trials

Trials by the same sponsor.

NCT07068074 — A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients · Phase 3 · not yet recruiting
NCT07040280 — Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Pati · Phase 2 · not yet recruiting
NCT07122492 — A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude) · NA · not yet recruiting
NCT07085728 — Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatm · Phase 2 · not yet recruiting
NCT06756607 — The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01487733 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eastern Cooperative Oncology Group
Last refreshed: 17 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01487733.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing